Lupin Launches FDA-Approved Generic Topiramate Extended-Release Capsules in Multiple Strengths

Lupin has introduced Topiramate Extended-Release Capsules in the United States market. The pharmaceutical company announced the launch of this product, which is a generic equivalent of Qudexy XR® Extended-Release Capsules, approved by the U.S. Food and Drug Administration (FDA). The capsules are available in multiple dosage strengths, including 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.

Topiramate is primarily prescribed for the treatment of epilepsy and migraine prevention. According to IQVIA MAT data as of December 2025, annual sales for Topiramate Extended-Release Capsules in the U.S. were approximately $133 million. Lupin’s entry into this market adds another option for patients requiring extended-release formulations of topiramate.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 4, 2026

Author

GOAI